Tokyo Tech Research Confirms Ease of Conversion of Zenyatta's Albany Graphite to Graphene

Zenyatta Ventures Ltd. (“Zenyatta” or “Company”) (TSXV: ZEN) today reported that researchers in Japan have published findings in the Journal of Materials Science linking particle size to the ease of producing graphene from graphite through exfoliation – the smaller the feed graphite particle, the easier to exfoliate. The researchers further concluded that, due to the size of its flakes, the exfoliation productivity of graphite derived from Zenyatta’s unique Albany deposit in Northern Ontario performed up to 1500% better than the researchers’ reference flake graphite materials. In a 2017 Zenyatta news release, Dr. Yoshihiko Arao, Assistant Professor in the Department of Chemical Engineering at Tokyo Tech, stated “Zenyatta’s high-purity graphite material was tested by our scientific team on mechanical conversion to graphene and discovered it converted much easier and with higher yields of graphene than our reference material. We have tested many types of natural graphite but found Zenyatta’s Albany Graphite material to have better exfoliation performance and produce better graphene particles than the reference material. We believe that this is an extraordinary, unique material and we would like to carry out further collaborative work with Zenyatta on graphene applications.” The following significant test results are reported in the paper by Dr. Arao and Dr. Masatoshi Kubouchi at Tokyo Tech:
  1. The main conclusion of the paper was that the smaller the feed graphite particle, the easier it is to exfoliate thus indicating that the graphite particle size is quite an important variable for successful exfoliation.
    • Exfoliation productivity of smaller Albany Graphite flakes performs up to 1500% better than the larger reference flake graphite materials.
    • Albany Graphite particles reach a 2 μm particle size with a standard milling process, while the reference flake graphite material could not mill below a 3 μm particle size as the graphite tends to agglomerate together.
    • It is concluded that the fine crystalline nature of Albany Graphite contributes to the relatively easy milling characteristics. This can be attributed to the unusual geological mode of formation (a rapid crystallization igneous process) which accounts for the superior crystallinity and overall quality of the graphite mineralization found in this unique deposit.
  2. Graphene exfoliated from Albany graphite produced material with the highest aspect ratio with an average thickness of 2.0 nm indicative of graphene with 2.4 layers. Also, the optical absorbance of the Zenyatta graphene dispersion was 2-10 times better than the other 3 reference samples that were tested. This demonstrated that concentrated graphene dispersions can be easily produced from Albany Graphite. The resulting small and thin graphene dispersion is suitable for printable inks.
This paper confirms the reason for success on the Company’s many graphene research and product development initiatives, especially in composites. Tokyo Tech has established that Zenyatta’s Albany Graphite converts (exfoliates) easily to graphene, producing mono-layer to tri-layer material with excellent dispersion properties and is highly suitable for many graphene and graphene-oxide applications. Mr. Peter Wood, P.Eng, P.Geo., President and COO of Zenyatta, is the “Qualified Person” for the purposes of National Instrument 43-101 and has reviewed, prepared and supervised the preparation of the technical information contained in this news release. For further information: Dr. Francis Dubé, Co-CEO & Head of Business Development and Technology Tel: +1 (289) 821-2820 Email: fdube@zenyatta.ca
  • Share

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.com.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Tyler Dunn

Director, Marketing & Communications

tdunn@zentek.com

Subscribe for Updates

Interested in recieving press releases directly to your inbox? Subscribe to Zentek's mailing list for all the latest news.